Digoxin is an oral pharmaceutical that was primarily used to treat heart failure and atrial fibrillation, but is also capable of inhibiting NKA activity and affecting the expression of NKA‐associated genes (Ren et al., 2021). This evidence concerns the gene TAC1 and atrial fibrillation.